港股异动 | CRO概念股集体高开生物安全法案未被列入美参众两院最终版NDAA

智通财经2024-12-09

智通财经APP获悉，CRO概念股集体高开，截至发稿，药明生物(02269)涨13.03%，报19.6港元；药明康德(02359)涨11.72%，报61港元；康龙化成(03759)涨9.14%，报16港元；昭衍新药(06127)涨6.2%，报9.93港元；金斯瑞生物科技(01548)涨4.98%，报11.8港元。消息面上，当地时间12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490762502?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-09 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490762502","market":"sh","top_or_hot":-1,"title":"港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，CRO概念股集体高开，截至发稿，药明生物(02269)涨13.03%，报19.6港元；药明康德(02359)涨11.72%，报61港元；康龙化成(03759)涨9.14%，报16港元；昭衍新药(06127)涨6.2%，报9.93港元；金斯瑞生物科技(01548)涨4.98%，报11.8港元。消息面上，当地时间12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1221928.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 09:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1221928.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，CRO概念股集体高开，截至发稿，药明生物(02269)涨13.03%，报19.6港元；药明康德(02359)涨11.72%，报61港元；康龙化成(03759)涨9.14%，报16港元；昭衍新药(06127)涨6.2%，报9.93港元；金斯瑞生物科技(01548)涨4.98%，报11.8港元。消息面上，当地时间12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1221928.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1221928.html","article_id":"2490762502","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490762502","pubTimestamp":1733707405,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，当地时间12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案最终协议文本，该版本兼顾了众议院以及参议院两方的提案。NDAA最新版本显示，生物安全法案未被列入其中。按照流程，该版本要获得美国总统签字之后才能生效。招银国国际认为，这意味着生物安全法案试图通过加入NDAA的立法路径失败。生物安全法案仍可以推进单独立法，但考虑到仅剩两周窗口期，该行认为单独立法的成功率极低。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02269":"药明生物","06127":"昭衍新药","LU0359201612.USD":"贝莱德中国基金A2","01548":"金斯瑞生物科技","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","NDAA":"NED Davis Research 360 Dynamic Allocation Etf","BK1583":"高瓴概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","03759":"康龙化成","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1521":"挪威政府全球养老基金持仓","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","02359":"药明康德","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1589":"北水核心资产","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","BK1610":"ETF&股票定投概念","LU0140636845.USD":"施罗德大中华区股票A Acc","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU0823426480.USD":"法巴中国股票经典Dis","BK1141":"生命科学工具和服务","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC"},"translate_title":"Changes in Hong Kong stocks, CRO concept stocks collectively opened higher, and the biosafety bill was not included in the final version of the NDAA of the US House and Senate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9,"01548":0.9,"02359":0.9,"NDAA":1,"03759":0.9,"06127":0.9},"content_text":"智通财经APP获悉，CRO概念股集体高开，截至发稿，药明生物(02269)涨13.03%，报19.6港元；药明康德(02359)涨11.72%，报61港元；康龙化成(03759)涨9.14%，报16港元；昭衍新药(06127)涨6.2%，报9.93港元；金斯瑞生物科技(01548)涨4.98%，报11.8港元。消息面上，当地时间12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案（NDAA）最终协议文本，该版本兼顾了众议院以及参议院两方的提案。NDAA最新版本显示，生物安全法案未被列入其中。按照流程，该版本要获得美国总统签字之后才能生效。招银国国际认为，这意味着生物安全法案试图通过加入NDAA的立法路径失败。生物安全法案仍可以推进单独立法，但考虑到仅剩两周窗口期，该行认为单独立法的成功率极低。民生证券指出，美联储降息50bp，biotech融资端有望延续上半年改善趋势，以海外客户为主要订单和收入贡献的CXO龙头有望进一步回暖。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490762502","isCrawlerRequest":true}

港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA

精彩评论

港股异动 | CRO概念股集体高开生物安全法案未被列入美参众两院最终版NDAA